Indeed, NBS for spinal muscular atrophy is nowadays largely accepted amongst pediatricians, families and advocacy groups, although screening assays specifically focus only on the identification of homozygotic deletions of the SMN1 gene and miss SMN1 heterozygotic and SMN2 deletions. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.